| Document |
Document Title |
|
WO/2024/059495A1 |
Provided herein are methods for preparing intermediate amide compounds for the preparation of ergoline analogs.
|
|
WO/2024/028495A1 |
The present invention relates generally to substituted ergoline compounds and compositions, more particularly new lysergamide derivatives and compositions, and applications of these. The invention furthermore relates to a new production ...
|
|
WO/2023/250298A1 |
A composition of a compound represented generically by FIGURE 1A for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIGURE 1A to a mammal, ...
|
|
WO/2023/220381A1 |
Methods of preparation of lysergic acid and derivatives thereof. Methods of using lysergic acid and derivatives thereof, such as methods of treating neurodegenerative disorders. Derivatives of lysergic acid and pharmaceutically acceptabl...
|
|
WO/2023/141636A1 |
Disclosed herein are 2-bromo-LSD analogs of Formula (I) or a pharmaceutically acceptable salt thereof, as well as methods for making and using the compounds to, for example, treat neuropsychiatric disorders.
|
|
WO/2023/115006A1 |
Disclosed herein are isotopically enriched compounds of 2-bromolysergic acid diethylamide, LSD, ALD-52, and 1P-LSD, as well as methods for their use in treating neurologic and brain disorders.
|
|
WO/2023/108277A1 |
The present invention relates to application of hydrotropic agents in making water-soluble and super-fast disintegrating tablets, buccal tablets, or sublingual tablets containing either cannabinoid molecules or psychedelics molecules. Th...
|
|
WO/2023/107966A1 |
Disclosed herein are salts and solid forms of LSD, 1-acetyl-LSD, 1-propionyl-LSd, and 2-bromo-LSD. The solid form may be a salt and/or a crystalline form of the LSD, 1-acetyl-LSD, 1-propionyl-LSd, or 2-bromo-LSD, such as a polymorph of L...
|
|
WO/2023/073423A1 |
Provided herein are novel lisuride compounds, processes for their preparation, compositions comprising said compounds, and use in therapy. More particularly, the present disclosure relates to fluorinated and/or deuterated analog useful i...
|
|
WO/2023/018480A1 |
A compound, or a pharmaceutically acceptable salt thereof, of formula I wherein R1, R8, R9, R31, R32, R33, and R34 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl; and R2, R4, R5, R6, and R7 are each independently H, F,...
|
|
WO/2023/012691A1 |
The present disclosure relates to the transdermal administration of pharmaceutical agents, such as CBD, THC, psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment a...
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2022/246572A1 |
The present application relates to combination compositions comprising one or more hallucinogens, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and one or more fatty acids, or a pharmaceutically acceptable salt, ...
|
|
WO/2022/221942A1 |
Implantable product(s) and methods for predetermined release of one or more active pharmaceutical ingredients (APIs). More specifically, implantable, subcutaneous product(s) and methods for treating depression and other mental and/or moo...
|
|
WO/2022/226408A1 |
The present disclosure provides ergoline compounds and their use in treating mood disorders. Pharmaceutical compositions and methods of making various ergoline compounds are provided.
|
|
WO/2022/198315A1 |
Methods for treatment of mental and/or mood disorders in a subject are disclosed. The methods comprise administration to a subject in need thereof an effective amount of 2-bromo-LSD and/or a mTOR inhibitor. Also disclosed are pharmaceuti...
|
|
WO/2022/187953A1 |
The present disclosure concerns imaging agents and triggers for assessing, in a non-invasive manner, a response of a myocardium of a subject to a vascular spasm. The imaging agents and triggers are used to obtain dynamic myocardial perfu...
|
|
WO/2022/153266A1 |
This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
|
|
WO/2022/133604A1 |
Methods using 2-Bromo-LSD or a derivative or salt thereof to treat subjects suffering from mental and/or mood disorders. The 2-Bromo-LSD is provided as a pharmaceutical composition formulated in a variety of manners for resolving symptom...
|
|
WO/2022/129437A1 |
The present application relates to long Stokes shift chromenoquinoline dyes and their uses as fluorescent labels. For example, these dyes may be used to label nucleotides for nucleic acid sequencing applications. The chromenoquinoline dy...
|
|
WO/2022/107095A1 |
Disclosed are methods of treating pain, such as headaches, comprising administering an ergotamine and thymoquinone, wherein the ergotamine is selected from the group consisting of BOL-148, lysergic acid diethylamide (LSD), and lysergic a...
|
|
WO/2022/023813A1 |
Disclosed herein are methods of treating neuropsychiatric and cognitive diseases, disorders, or conditions, such as social disfunction, with repeated doses of a modulator of the AMPA receptor and/or the 5-HT2A receptor.
|
|
WO/2022/008627A2 |
The present invention provides an improved method for the production of lysergic acid diethylamide (LSD) for GMP purposes. Furthermore, the present invention provides novel LSD derivatives of formula (I) as well as their synthesis and pu...
|
|
WO/2021/243461A1 |
Disclosed is a method of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication thereof, and/or altering the diet of an individual comprising administering DMT, LSD, LSA, or an analog thereof.
|
|
WO/2021/209815A1 |
The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethyl amine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention a...
|
|
WO/2021/081634A1 |
A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acety...
|
|
WO/2020/123607A1 |
Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches. The present disclosure provides new methods of medical treatment or prevention (e.g, f...
|
|
WO/2019/246532A1 |
The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro p...
|
|
WO/2019/083892A1 |
Embodiments of the present invention provide materials and methods for preventing and treating ergot-based toxicity in animals, including humans. In particular, the present disclosure provides materials and methods for ameliorating the h...
|
|
WO/2018/223065A1 |
The present invention provides novel neuromodulatory compounds and compositions thereof. The invention also relates to methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for p...
|
|
WO/2018/076019A1 |
A novel quantum-based computational process for drug discovery and design was used to identify potential novel liver-stage anti-malarial therapeutic molecules. The approach combined the latest big-data advances in high-throughput bioassa...
|
|
WO/2017/184875A1 |
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyper...
|
|
WO/2016/118541A1 |
Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...
|
|
WO/2015/051307A1 |
Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a β-elimination mechanism.
|
|
WO/2014/114664A1 |
The present invention relates to a process for producing 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) including salts and hydrates thereof of general formula (I) from the respective cyclen. Said process further i...
|
|
WO/2014/100354A1 |
Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migr...
|
|
WO/2014/078857A1 |
The invention provides compounds of formula (I) wherein R1-R4 have any of the values defined in the specification, and salts thereof. The compounds are useful as dopamine receptor modulators for the treatment of diseases where modulation...
|
|
WO/2012/177962A1 |
Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...
|
|
WO/2012/001308A9 |
The present invention relates to a method for preparing structural analogues of tetracyclic, pentacyclic, and polycyclic ergoline alkaloids, in four steps, from an indole-3-carboxaldehyde, wherein the method includes the following two ke...
|
|
WO/2011/059463A1 |
This invention relates to deuterated indolocarbazole compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.
|
|
WO/2010/045527A1 |
The present invention is directed to methods and kits for the determining the presence or absence of ergot alkaloids in sample which use chromatographic instrumentation and columns operating at a pressure of 4,000 to 15,000 psi and colum...
|
|
WO/2010/000676A1 |
The present invention relates to a method for preparing microbiologically produced ergot alkaloids of the following formula (I), comprising the step of: a) extracting the fermentation product occurring during the biological production, s...
|
|
WO/2009/133097A1 |
A process for producing N-6 demethylated 9,10-dihydrolysergic acid alkyl ester is described, which comprises a step of N-6 demethylation of 9,10-dihydrolysergic acid alkyl esters with chloroformate and wherein the N-6 demethylation step ...
|
|
WO/2009/071607A2 |
The present invention relates to new Ergot alkaloid derivatives of the general formula (I) or pharmaceutically acceptable salts thereof as well as to the use of specific compounds as selective radical scavengers for neurons.
|
|
WO/2008/104956A2 |
The present invention relates to processes for the preparation of amorphous cabergoline by agitated thin film drying or spray drying.
|
|
WO/2008/092881A1 |
The present invention relates to a cabergoline crystal form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and to pharmaceutical compositions containing the new form.
|
|
WO/2008/049884A1 |
The present invention relates to a process for producing cabergoline crystal forms. The process comprises preparation of the desired solvate of cabergoline from a solution of cabergoline in chloroaromatic solvents. Afterwards cabergoline...
|
|
WO/2008/043601A2 |
The present invention relates to a transdermal therapeutic system (TTS) comprising an impermeable covering layer, a matrix containing an ergolin compound of formula (I) or the physiologically compatible salt or derivative thereof, wherei...
|
|
WO/2007/091039A2 |
The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.
|
|
WO/2007/012846A1 |
A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides...
|
